Adjuvant Nivolumab as Standard of Care in Resected Bladder Cancer

Extended follow-up from the CheckMate 274 trial further supports adjuvant nivolumab as a standard of care for patients with resected muscle-invasive urothelial carcinoma.
Medscape Medical News

source https://www.medscape.com/viewarticle/988496?src=rss

Comments

Popular posts from this blog

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?